Rakuten Medical, Inc.
https://rakutenmedical.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Rakuten Medical, Inc.
Finance Watch: BioAge Raises $198m In 20th Biopharma IPO Of 2024
Public Company Edition: BioAge will fund a Phase II trial of its muscle atrophy prevention drug in combination with an obesity drug with its initial public offering proceeds. Also, Ascendis and Wave raised $281.3m and $200m, respectively, after positive clinical trial readouts.
MBX, Zenas And Bicara IPOs Generate Big First Day Returns, But Will They Last?
MBX, Zenas and Bicara delivered positive returns in their first days of trading, but that has not always translated to good long-term results for drug developers that launched US IPOs this year.
Finance Watch: Zenas, Bicara, MBX Aim To Raise $100m Or More In Future IPOs
Fifteen biopharma firms have launched IPOs in the US this year, but three more have joined the queue. Also, Galderma sold CHF500m ($590.7m) in bonds to pay down debt, Noetik raised a $40m series A round and ImCheck collected €20.18m ($22.4m) from the French government.
Finance Watch: Fresh Cash For Life Science Firms From venBio, Symbiotic
Private Company Edition: Symbiotic Capital emerged with a $600m-plus fund to provide credit for private and public companies, while venBio raised a $528m fund. Also, Outpace Bio raised $144m, Jade Biosciences launched with $80m and MBX Biosciences raised $63.5m.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- ADMET
- Other Names / Subsidiaries
-
- Aspyrian Therapeutics Inc.
- Rakuten Aspyrian Inc.
- Medlight SA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice